Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome
- PMID: 26166206
- PMCID: PMC4562880
- DOI: 10.1016/j.neurobiolaging.2015.06.020
Candidate genes for Alzheimer's disease are associated with individual differences in plasma levels of beta amyloid peptides in adults with Down syndrome
Abstract
We examined the contribution of candidates genes for Alzheimer's disease (AD) to individual differences in levels of beta amyloid peptides in adults with Down syndrom, a population at high risk for AD. Participants were 254 non-demented adults with Down syndrome, 30-78 years of age. Genomic deoxyribonucleic acid was genotyped using an Illumina GoldenGate custom array. We used linear regression to examine differences in levels of Aβ peptides associated with the number of risk alleles, adjusting for age, sex, level of intellectual disability, race and/or ethnicity, and the presence of the APOE ε4 allele. For Aβ42 levels, the strongest gene-wise association was found for a single nucleotide polymorphism (SNP) on CAHLM1; for Aβ40 levels, the strongest gene-wise associations were found for SNPs in IDE and SOD1, while the strongest gene-wise associations with levels of the Aβ42/Aβ40 ratio were found for SNPs in SORCS1. Broadly classified, variants in these genes may influence amyloid precursor protein processing (CALHM1, IDE), vesicular trafficking (SORCS1), and response to oxidative stress (SOD1).
Keywords: Biomarkers; Down syndrome; Genetics; β Amyloid peptides.
Copyright © 2015 Elsevier Inc. All rights reserved.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures
Similar articles
-
SORL1 gene, plasma biomarkers, and the risk of Alzheimer's disease for the Han Chinese population in Taiwan.Alzheimers Res Ther. 2016 Dec 30;8(1):53. doi: 10.1186/s13195-016-0222-x. Alzheimers Res Ther. 2016. PMID: 28034305 Free PMC article.
-
CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.Mol Med. 2011 Sep-Oct;17(9-10):974-9. doi: 10.2119/molmed.2011.00154. Epub 2011 May 24. Mol Med. 2011. PMID: 21629967 Free PMC article.
-
Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome.Neurosci Lett. 2001 Apr 6;301(3):199-203. doi: 10.1016/s0304-3940(01)01657-3. Neurosci Lett. 2001. PMID: 11257432
-
Genetic and host factors for dementia in Down's syndrome.Br J Psychiatry. 2002 May;180:405-10. doi: 10.1192/bjp.180.5.405. Br J Psychiatry. 2002. PMID: 11983636 Review.
-
Alzheimer's disease: its proteins and genes.Cell. 1988 Feb 12;52(3):307-8. doi: 10.1016/s0092-8674(88)80021-7. Cell. 1988. PMID: 2964275 Review. No abstract available.
Cited by
-
Dementia in Down syndrome: unique insights for Alzheimer disease research.Nat Rev Neurol. 2019 Mar;15(3):135-147. doi: 10.1038/s41582-018-0132-6. Nat Rev Neurol. 2019. PMID: 30733618 Free PMC article. Review.
-
Synthetic combinations of missense polymorphic genetic changes underlying Down syndrome susceptibility.Cell Mol Life Sci. 2016 Nov;73(21):4001-17. doi: 10.1007/s00018-016-2276-0. Epub 2016 May 31. Cell Mol Life Sci. 2016. PMID: 27245382 Free PMC article. Review.
-
Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study.PLoS One. 2017 Jul 13;12(7):e0180046. doi: 10.1371/journal.pone.0180046. eCollection 2017. PLoS One. 2017. PMID: 28704393 Free PMC article.
-
Candidate gene analysis for Alzheimer's disease in adults with Down syndrome.Neurobiol Aging. 2017 Aug;56:150-158. doi: 10.1016/j.neurobiolaging.2017.04.018. Epub 2017 May 3. Neurobiol Aging. 2017. PMID: 28554490 Free PMC article.
-
What Can We Learn About Alzheimer's Disease from People with Down Syndrome?Curr Top Behav Neurosci. 2025;69:197-226. doi: 10.1007/7854_2024_546. Curr Top Behav Neurosci. 2025. PMID: 39509049 Review.
References
-
- Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, Compton D, Spurlock G, Turic D, Hoogendoorn B, Kwon JM, Petersen RC, Tangalos E, Norton J, Morris JC, Bullock R, Liolitsa D, Lovestone S, Hardy J, Goate A, O’Donovan M, Williams J, Owen MJ, Jones L. Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer’s disease. Human Genetics. 2001;109(6):646–52. - PubMed
-
- Aylward EH, Burt DB, Thorpe LU, Lai F, Dalton A. Diagnosis of dementia in individuals with intellectual disability. J Intellect Disabil Res. 1997;41 ( Pt 2):152–64. - PubMed
-
- Benitez BA, Karch CM, Cai Y, Jin SC, Cooper B, Carrell D, Bertelsen S, Chibnik L, Schneider JA, Bennett DA, Fagan AM, Holtzman D, Morris JC, Goate AM, Cruchaga C Alzheimer’s Disease Neuroimaging I, Genetic Environmental Risk for Alzheimer’s Disease Consortium G. The PSEN1, p.E318G variant increases the risk of Alzheimer’s disease in APOE-epsilon4 carriers. PLoS Genetics. 2013;9(8):e1003685. doi: 10.1371/journal.pgen.1003685. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous